Adams Respiratory kept at sector perform by RBC

RBC Capital Markets analyst Ken Trbovich kept Adams Respiratory Therapeutics Inc. at sector perform, above average risk, and a $50 price target. The company's Fort Worth, Texas, facility buyback should improve margins and be slightly accretive in 2007, according to the analyst. Adams will pay $24 million upfront and an additional $4 million over the remainder of 2007. The purchase price includes about $11 million of inventory and $7 million in manufacturing assets. Shares of the Chester, N.J.-based pharmaceutical company were up 1 cent, or 0.02%, at $44.00, on volume of 148,247 shares versus the three-month running average of 293,354 shares. (Nasdaq: ARXT)

Charles River Lab on hold by Jefferies

Jefferies & Co., Inc. analyst David Windley rated Charles River Laboratories International Inc. at hold after the company reported mixed quarterly results. The company reported non-GAAP earnings per share of $0.57. Sales of $267.8 million beat the analyst's estimate of $265.7 million. Management reiterated its 2006 non-GAAP guidance of $2.12 to $2.18. Shares of the Wilmington, Mass.-based research company were up $4.43, or 13.06%, at $38.35, on volume of 4,022,800 shares versus the three-month running average of 986,642 shares. (NYSE: CRL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.